LTT462X
Total Payments
$650,923
Transactions
8
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $873.00 | 2 | 1 |
| 2019 | $168,819 | 2 | 0 |
| 2018 | $233,222 | 2 | 0 |
| 2017 | $248,010 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $650,923 | 8 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I DOSE FINDING STUDY OF ORAL LTT462 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS HARBORING MAPK PATHWAY ALTERATIONS | Novartis Pharmaceuticals Corporation | $650,664 | 0 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $259.00 | 1 |
Top Doctors Receiving Payments for LTT462X
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $650,664 | 7 |
| , M.D, PHD | Internal Medicine | Houston, TX | $259.00 | 1 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $650,923
Product Information
- Type Drug
- Total Payments $650,923
- Total Doctors 1
- Transactions 8
About LTT462X
LTT462X is a drug associated with $650,923 in payments to 1 healthcare providers, recorded across 8 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $873.00 was paid across 2 transactions to 1 doctors.
The most common payment nature for LTT462X is "Unspecified" ($650,923, 100.0% of total).
LTT462X is associated with 2 research studies, including "A PHASE I DOSE FINDING STUDY OF ORAL LTT462 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS HARBORING MAPK PATHWAY ALTERATIONS" ($650,664).